ANTISENSE INHIBITION OF HIV INFECTION

Information

  • Research Project
  • 2065220
  • ApplicationId
    2065220
  • Core Project Number
    R43AI029801
  • Full Project Number
    1R43AI029801-01
  • Serial Number
    29801
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/24/1990 - 33 years ago
  • Project End Date
    3/23/1991 - 33 years ago
  • Program Officer Name
  • Budget Start Date
    9/24/1990 - 33 years ago
  • Budget End Date
    3/23/1991 - 33 years ago
  • Fiscal Year
    1990
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/24/1990 - 33 years ago
Organizations

ANTISENSE INHIBITION OF HIV INFECTION

The goal of the proposed Phase I experimental plan is to use specific antisense sequences to inhibit, in vitro, acute infection of lymphoid cells by HIV. During Phase I this study will include three major areas of experimental work: 1. Examination of the process of DNA replication and integration during HIV infection of lymphoid cell lines using in situ hybridization and in vitro analysis of nuclear DNA. 2. Examination of the effects of known inhibitors of the early phase of HIV infection on this process. 3. Design and testing of specific antisense RNA constructs for inhibition of acute infection of lymphoid cells. Because latency is established during acute infection of cells by HIV, the antisense constructs developed in this work may be useful for preventing the establishment of latency. During continuing phases, these and new constructs will be used to prevent the activation of HIV from latently infected cells. Appropriate delivery vectors containing effective antisense constructs will then be developed. The proposed research program has significance in two areas: it will increase our understanding, of the virology and pathology of HIV and it will have an impact on efforts designed to control the infectious process and the disease. Antisense constructs and antisense manipulation of blood stem cells of ADDS patients eventually may be used to control the expression of HIV in chronically infected cans, to prevent the activation of HIV from the chronically infected cells, and to prevent the infection of newly generated, or introduced, previously uninfected cells.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    ENZO BIOCHEM, INC.
  • Organization Department
  • Organization DUNS
    081664328
  • Organization City
    FARMINGDALE
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    11735
  • Organization District
    UNITED STATES